Mayo Clinic Develops Test to Distinguish Other Demyelinating Diseases from MS

Mayo Clinic Develops Test to Distinguish Other Demyelinating Diseases from MS

“Certain drugs will prevent disease relapses and may reduce [patients’] disability progression, so this diagnostic information will help healthcare providers and their patients with treatment options,” Dr. said Andrew McKeon, the other co-director of Mayo’s neuroimmunology laboratory.

McKeon believes a combination of the Mayo test and an aquaporin-4 (AQP4) test offer doctors “the most comprehensive evaluation for patients recently diagnosed with demyelinating diseases.”

The AQP4 test looks for antibodies against the AQP4 protein, which works as a water channel in cell membranes. The AQP4 antibody, which Mayo Clinic researchers discovered more than a decade ago, was the first biomarker for inflammatory demyelinating diseases.

Pittock encourages people who are experiencing sudden vision problems, such as difficulty seeing and eye pain, to take the two antibody tests.

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
×
Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.
Latest Posts
  • Mayzent Approved in Europe
  • DMTs and MS
  • DMTs and MS progression
  • FTO gene mutation

Pin It on Pinterest

Share This